Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 13 July, 2012 and appeared in  MedicationGLP-1 Receptor Agonist TherapyPathologyIssue 634Maximizing the Benefits of GLP-1

Incretin Effect Independent of Glycemia Level

Healthy individuals without diabetes have similar increases in insulin secretion....

Advertisement

The enhanced insulin secretion after meals mediated by two intestinal hormones, known as the incretin effect, is independent of glycemia in healthy individuals, according to a study.

To examine the role of plasma glycemia on the incretin effect, Marzieh Salehi, M.D., from the University of Cincinnati, and colleagues gave 13 healthy subjects without diabetes 50 g of an oral glucose solution mixed with D-xylose at two levels of fixed plasma hyperglycemia: 8 mmol/L and 10.5 mmol/L. The experiment was performed twice at the low glycemia level and once at the high level.

The researchers found that the relative increase in insulin secretion was similar at both glycemia levels. The response of the intestinal hormone glucagon-like peptide-1 (GLP-1) was significantly lower at higher plasma glycemia, while the response of glucose-dependent insulinotropic polypeptide was similar in all studies. The incretin effect was found to be reproducible.

"These findings indicate that the incretin contribution to postprandial insulin release is independent of glycemia in healthy individuals, despite differences in GLP-1 secretion," Salehi and colleagues conclude. "These findings suggest that in healthy humans, control of the magnitude of the incretin effect is complex and occurs primarily at the level of the gastrointestinal tract."

Diabetes, June 25, 2012

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 13 July, 2012 and appeared in  MedicationGLP-1 Receptor Agonist TherapyPathologyIssue 634Maximizing the Benefits of GLP-1

Past five issues: Diabetes Clinical Mastery Series Issue 141 | Issue 681 | Diabetes Clinical Mastery Series Issue 140 | Issue 680 | Diabetes Clinical Mastery Series Issue 139 |

 
Diabetes In Control Advertisers
 
Cast Your Vote
If the FDA relaxes prescribing restrictions on Avandia, will you recommend it?

Navigate Diabetes In Control
Search Articles On Diabetes In Control